4//SEC Filing
SILVERSTEIN JONATHAN 4
Accession 0000947871-20-000078
CIK 0001787306other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:27 PM ET
Size
21.1 KB
Accession
0000947871-20-000078
Insider Transaction Report
Form 4
SILVERSTEIN JONATHAN
Director10% Owner
Transactions
- Purchase
Common Stock
2020-02-03$17.00/sh+176,500$3,000,500→ 176,500 total(indirect: See Footnotes) - Conversion
Common Stock
2020-02-04+859,573→ 4,067,564 total(indirect: See Footnotes) - Conversion
Series B Preferred Stock
2020-02-04−2,825,603→ 0 total(indirect: See Footnotes)→ Common Stock (2,825,603 underlying) - Conversion
Common Stock
2020-02-04+2,825,603→ 3,207,991 total(indirect: See Footnotes) - Conversion
Common Stock
2020-02-04+429,786→ 606,286 total(indirect: See Footnotes) - Purchase
Common Stock
2020-02-03$17.00/sh+382,388$6,500,596→ 382,388 total(indirect: See Footnotes) - Conversion
Series C Preferred Stock
2020-02-04−859,573→ 0 total(indirect: See Footnotes)→ Common Stock (859,573 underlying) - Conversion
Series C Preferred Stock
2020-02-04−429,786→ 0 total(indirect: See Footnotes)→ Common Stock (429,786 underlying)
Footnotes (6)
- [F1]These shares of the Issuer's common stock ("Shares") were purchased in the Issuer's initial public offering.
- [F2]The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
- [F3]Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F4]The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPMF"). OrbiMed Capital is the investment manager of OPMF and is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPMF.
- [F5]The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.
- [F6]The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001171005
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 5:27 PM ET
- Size
- 21.1 KB